Activity of endovesical gemcitabine in BCG-refractory bladder cancer patients: a translational study

Intravesical gemcitabine (Gem) has shown promising activity against transitional cell carcinomas (TCC) of the bladder, with moderate urinary toxicity and low systemic absorption. The present phase II study evaluated the activity of biweekly intravesical treatment with Gem using a scheme directly der...

Descripción completa

Detalles Bibliográficos
Autores principales: Gunelli, R, Bercovich, E, Nanni, O, Ballardini, M, Frassineti, G L, Giovannini, N, Fiori, M, Pasquini, E, Ulivi, P, Pappagallo, G L, Silvestrini, R, Zoli, W
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2007
Materias:
Translational Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360270/
https://www.ncbi.nlm.nih.gov/pubmed/17987035
http://dx.doi.org/10.1038/sj.bjc.6604074

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360270/
https://www.ncbi.nlm.nih.gov/pubmed/17987035
http://dx.doi.org/10.1038/sj.bjc.6604074

Ejemplares similares